Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy following 24 weeks of treatment in patients. | June 13, 2023
Daix, 25 May 2023 Pursuant to Article 241-2 of the AMF General Regulations , the purpose of this description is to present the objectives and terms of the Company’s share repurchase. | May 25, 2023
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm’s subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in. | May 25, 2023
Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0. | May 16, 2023
Daix , Long Island City , May 4, 2023 – Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with. | May 4, 2023